Growth Hormone's Effect on Endothelial Progenitor Cells

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effect of short-term low-dose growth hormone therapy on the mobilization of endothelial progenitor cells from the bone marrow within a group of healthy adults.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Collaborator: National Center for Research Resources (NCRR)
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Adults age 18 thru 65

• Serum IGF-1 in the lower half of the age and gender-specific normal range at the time of screening visit

Exclusion Criteria:

• Systemic hypertension, as defined as current BP >140/90 on screening visit, or taking anti-hypertensive therapy.

• Diabetes mellitus, as defined by known diagnosis or Fasting Blood Glucose >126 at the time of screening visit.

• Women who are pregnant or nursing, as confirmed by history or seum beta-hCG at the time of screening visit.

• Women who are taking exogenous oral estrogens of any kind.

• Personal history of active cancer or recurrence within the past 10 years, with the exception of non-melanoma skin cancer.

• Personal history of an untreated benign intracranial neoplasm.

• Initiation of statin therapy during the course of the study.

• A serum IGF-1 level below the age and gender-specific normal range at the time of screening visit.

• Renal insufficiency, as defined by a GFR <60 mls/min/1.73 m2 upon Renal Function panel at the time of screening visit.

• Hepatic insufficiency, as defined by an AST and/or ALT >twice the upper limit of normal at the time of screening visit.